![2018 12 11 00 02 7009 Atom Nuclear Lab 400](https://img.auntminnieeurope.com/files/base/smg/all/image/2023/04/ame.2018_12_11_00_02_7009_atom_nuclear_lab_400.png?auto=format%2Ccompress&q=70&w=400)
ITM Isotope Technologies Munich and the Paul Scherrer Institute plan to co-develop the radionuclide terbium-161 (Tb-161) for cancer therapy.
The companies will combine their respective technologies and expertise toward developing a large-scale production process for Tb-161, which has shown promise in preliminary studies as a therapeutic radionuclide in prostate cancer.
This collaboration significantly expands ITM's production and development portfolio for medical isotopes in precision oncology, ITM said in a news release.